- Home
- SEGG vs BLRX Comparison
SEGG vs BLRX Comparison
Compare SEGG & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SEGG | BLRX |
|---|---|---|
| Founded | N/A | 2003 |
| Country | United States | Israel |
| Employees | 12 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.0M | 12.6M |
| IPO Year | 2023 | 2010 |
Fundamental Metrics
Financial Performance| Metric | SEGG | BLRX |
|---|---|---|
| Price | $1.09 | $2.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | ★ 1.1M | 9.4K |
| Earning Date | N/A | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.46 | $2.30 |
| 52 Week High | $7.61 | $7.77 |
Technical Indicators
Market Signals| Indicator | SEGG | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | 48.65 | 39.49 |
| Support Level | $1.06 | N/A |
| Resistance Level | $1.15 | $3.11 |
| Average True Range (ATR) | 0.11 | 0.17 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 56.72 | 17.20 |
Price Performance
Historical ComparisonAbout SEGG Lottery.com Inc.
Sports Entertainment Gaming Global Corp is a sports, entertainment and gaming group operating digital assets such as Sports.com and Lottery.com. It is focused on immersive fan engagement, ethical gaming and AI-driven live experiences.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.